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Infectious complications, particularly in the respiratory
tract of critically ill patients, are related to increased
mortality. Severe infection is part of a multiple system
illness and female patients with severe sepsis have a
worse prognosis compared to males. Kallistatin is a
protective hormokine released during monocyte
activation and low levels in the setting of septic shock
can predict adverse outcomes. Presepsin is another
biomarker that was recently evaluated and is elevated
in patients with severe sepsis patients at risk of dying.
The Centers for Disease Control and Prevention has
introduced new definitions for identifying patients at
risk of ventilator-associated complications (VACs), but
several other conditions, such as pulmonary edema and
acute respiratory distress syndrome, may cause VACs,
and not all patients with VACs may have ventilator-
associated pneumonia. New studies have suggested
strategies to identify patients at risk for resistant
pathogen infection and therapies that optimize efficacy,
without the overuse of broad-spectrum therapy in
patients with healthcare-associated pneumonia.
Innovative strategies using optimized dosing of
antimicrobials, maximizing the pharmacokinetic and
pharmacodynamic properties of drugs in critically ill
patients, and newer routes of drug delivery are being
explored to combat drug-resistant pathogens. We
summarize the major clinical studies on respiratory
infections in critically ill patients published in 2013.study, 53.6% of patients had respiratory tract infection asIntroduction
Critically ill patients with respiratory infections have been
the continued focus of investigation over the last several
years. Infections, mostly nosocomial, are a major cause of
mortality in hospitalized patients related to an increased
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unless otherwise stated.and the widespread use of indiscriminate broad-spectrum
antibiotics. The frequency and epidemiology of MDR
pathogens show regional variation, however, with several
studies pointing out that the risk of MDR pathogens in
healthcare-associated pneumonia (HCAP) is variable and
hence there is a need for accurate risk scoring in this
category of patients. Obtaining meaningful data and
monitoring trends of preventative strategies have become
ever more important, with the Centers for Disease Control
and Prevention (CDC) recently publishing new surveillance
definitions. Newer biomarkers are becoming part of
the increasing armamentarium in the field of critical care
medicine and antibiotic stewardship using biomarkers
has been studied robustly. Antibiotic use in the critically
ill, with dosing to attain better pharmacokinetic and
pharmacodynamic results, was part of several research
studies. We summarize the findings from the major
clinical research studies published in 2013 on respiratory
infections, with a focus on infections in critically ill patients.Risk factors and outcomes
Respiratory infection continues to be the most common
cause of sepsis and septic shock. The past decade has
seen increased awareness in recognizing patients with
sepsis and several guidelines, including the ‘Surviving
Sepsis Campaign’, have published a detailed framework
on the approach to patients with severe sepsis. In a large,
prospective, French, multicenter, observational study as
part of the EPISS study cohort, investigators examined the
epidemiology of septic shock in 1,495 patients [1]. In this
the cause of septic shock and 83.9% required invasive
mechanical ventilation (MV), with Gram-negative bacilli
being the most common pathogens identified. Although
most patients received initial appropriate antibiotic
therapy (n = 898), the in-hospital mortality rate was
still high, up to 48.7%. A higher Sequential Organ Failure
Assessment (SOFA) score, age and chronic health status
score and the presence of immunosuppression were
independent risk factors for short-term mortality. In a
follow-up study of the same cohort of patients, 3-month
mortality was 52.2%. Severity of illness, indicated by a
higher SOFA score early after septic shock, impactedCentral Ltd. The licensee has exclusive rights to distribute this article, in any
ion. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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as cirrhosis, nosocomial infection and age influenced
mortality after hospitalization [2].
In another prospective observational cohort of 1,000
patients with severe sepsis, Phua and colleagues studied
the characteristics and outcomes of patients with a positive
microbial culture (58.5%) compared with those whose
culture was negative (41.5%) [3]. Respiratory infection
was the most common cause of sepsis in both groups,
and a lung source was determined as the primary
cause of sepsis more often in patients with a negative
culture than in patients with a positive culture (74.5%
versus 59.9, P <0.001). Of all the pathogens identified,
infection with Pseudomonas aeruginosa (PA) was associated
with increased mortality (odds ratio (OR) 2.02, 95%
confidence interval (CI) 1.08 to 3.79, P = 0.03). Patients
with culture-negative sepsis had fewer comorbidities;
these patients were more often women and had lower
severity of illness than those with culture-positive
sepsis. Although patients with positive culture had
higher mortality, it was not an independent predictor
of mortality on logistic regression analysis. Sakr and
colleagues [4] studied the influence of gender on
3,902 patients with severe sepsis and found the frequency
of severe sepsis and septic shock was lower in women than
in men (6.0% versus 8.9%, P = 0.001) and the overall ICU
mortality was not different in both sexes (20.1% versus
19.8%, P = 0.834). In the subset of patients with
severe sepsis, however, female patients had worse
survival than men (63.5% versus 46.4%, P = 0.007).
Further studies on the impact of gender-specific
hormonal and immunologic profile differences may
uncover an explanation for these findings.
Cognitive dysfunction has been noted in patients
following severe illness. In a study including 5,888
participants, the authors tested the hypothesis that a
bidirectional relationship exists between pneumonia
and dementia, with subclinical changes in cognition
increasing the risk of pneumonia hospitalization and
an accelerated decline in cognitive dysfunction occurring
after pneumonia [5]. Three trajectories were identified
longitudinally based on Teng’s modified mini mental state
examination - no decline, minimal decline and severe
decline. A low cognitive score prior to hospitalization
increased the risk of pneumonia - a 10 point lower
modified mini mental state score increased the hazard
of pneumonia by 8.4%. Patients who had at least one
episode of pneumonia had a higher risk of developing
subsequent dementia than those without pneumonia
(hazards ratio 2.24, 95% CI 1.62 to 3.11, P = 0.01). Of the
total population, 6.8% had severe sepsis and similar cogni-
tive decline as was seen with pneumonia. Neurotoxicity
related to elevated cytokine levels and other co-morbid
conditions with severe illness, such as delirium, could be aplausible explanation for the cognitive decline. However,
the population in this study who developed pneumonia
were slightly older and had abnormal scores on mini
mental state examination and potentially were identified
earlier in their course with longitudinal screening.
Enteral feeding is the desired mode of nutritional
supplementation in critically ill patients, but patients
receiving enteral nutrition may have gastroparesis and
gastroesophageal reflux, putting them at risk for aspiration;
therefore, measurement of gastric residual volume (GRV)
is recommended in ventilated patients. Reignier and
associates [6] in a randomized, non-inferiority, open-label,
multicenter trial studied whether GRV monitoring every
6 hours and adjusting enteral feeding rates if the volume
exceeded 250 ml would prevent ventilator-associated
pneumonia (VAP). In this study, there was no difference
in VAP incidence between patients who had GRV
measured (n = 227) compared with the group (n = 222)
who did not (16.7% versus 15.8%), and all the clinical out-
comes, including mortality, were similar in both groups.
Patients in whom GRV was not measured had a higher
incidence of vomiting, but also a higher proportion of this
group achieved the calorie target and had lower use of
prokinetic agents. Although the study was done well,
it was underpowered to determine the harmful effects
related to vomiting and included mostly patients in the
medical ICU and excluded patients with gastrointestinal
bleeding. In a meta-analysis of 19 randomized controlled
trials including 1,394 patients, Alhazzani and colleagues [7]
reviewed the risk of pneumonia in patients receiving small
bowel feeding compared to gastric feeding. Small bowel
feeding was associated with reduced risk of pneumonia
(relative risk 0.70, 95% CI 0.55 to 0.90, P = 0.004), but there
was no difference in mortality, ventilator days or ICU
length of stay (LOS) between the two groups. The study is
limited, however, because the individual trials had small
sample sizes, included severe pancreatitis patients and
patients not in the ICU and used variable definitions of
pneumonia. Insertion of the small bowel feeding tube
can be technically difficult if done blindly and may
need additional training with fluoroscopy and endoscopy
procedures. Even though oropharyngeal bacterial transloca-
tion seems a likely cause of the development of VAP, it is
unclear if monitoring gastric reserve volume or advancing
the feeding tube to the small intestine clearly prevents VAP.
Another identified risk factor for ventilator-associated re-
spiratory infection (including VAP and ventilator-associated
tracheobronchitis) is iatrogenic immune suppression
(OR 3.34), a risk factor that has frequently been excluded
in prior studies [8].
Shorr and colleagues [9] studied the factors leading to
30-day readmission in 977 culture-proven non-nosocomial
pneumonia patients who survived to discharge following
initial hospitalization to any of the nine participating
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rate was 19.3% (n = 149) within the 30-day period and
was related to non-pneumonia causes such as chronic
obstructive pulmonary disease (25%) and congestive heart
failure (CHF) (22%). While pneumonia accounted for only
7.4% (n = 11) of readmissions, patients with HCAP were
re-admitted more often than those with community-
acquired pneumonia (CAP) (24.4% versus 4.1%, P <0.001)
and had more comorbid conditions. The four independent
variables associated with readmission on logistic regres-
sion analysis were long-term care admission prior to index
hospitalization (OR = 2.15, P = 0.001), immunosup-
pressed state (OR = 1.93, P = 0.001), previous antibiotics
(OR = 1.74, P = 0.009) and previous 90-day hospitalization
(OR = 1.66, P = 0.014). These data suggest that readmis-
sion rates differ among groups of patients with pneumo-
nia, and that patients with HCAP and those with
baseline poor functional status have a higher likelihood of
being readmitted than uncomplicated CAP patients.
Role of biomarkers
Clinical algorithms based on biomarkers help with antibiotic
de-escalation and possibly limit antibiotic over-exposure in
patients with pneumonia, but their use in clinical practice
has been variable. Procalcitonin (PCT), an inflammatory
hormokine, is elevated in bacterial infection and helps with
antibiotic stewardship, and risk stratification, particularly
for respiratory infections. Presepsin (sCD14-ST) is another
novel biomarker (soluble amino-terminal fragment of the
cluster of differentiation (CD) marker protein CD14) in
sepsis that is released into the circulation during monocyte
activation. Kallistatin is an endogenous serine proteinase
inhibitor that has a strong affinity to tissue kallikrein
and is thought to have a protective role with a higher
consumption in patients with severe sepsis.
In a prospective observational study of 54 severe
CAP patients admitted to ICU, Lin and colleagues
[10] determined the prognostic value of serum kallistatin
and its correlation to other biomarkers; 17 healthy
patients were included as controls. Plasma kallistatin and
antithrombin III were significantly lower on days 1 and 4
in patients who did not survive (24%) compared to those
who did, possibly indicating greater consumption of these
factors in the severely ill. The plasma kallistatin levels
were significantly reduced in patients with septic
shock and in those who developed acute respiratory
distress syndrome (ARDS). A cutoff level of day 1
kallistatin <6.5 μg/ml can discriminate between survivors
and non-survivors with an area under the curve
(AUC) of 0.683, P = 0.04 (Figure 1). Thus, decreased
plasma kallistatin level on day 1 of ICU admittance is
independently associated with mortality and severity of
disease in CAP patients in this study. In a multicenter,
case–control study, Masson and colleagues [11] comparedpresepsin and PCT levels in 50 survivors and 50 non-
survivors who were admitted to ICU with severe sepsis.
The presepsin levels were significantly higher on day 1 of
enrollment in patients who died compared with survivors
and remained significantly elevated on day 7 as well.
Presepsin was independently associated with short-term
ICU and 28-day mortality and had good prognostic
accuracy similar to the SOFA score for long-term
mortality at 90 days. PCT on the other hand was not
related to mortality and the levels declined on day 7
in both survivors and non-survivors.
CHF may cause gut translocation of bacteria and
potentially lead to elevated PCT levels. Wang and
colleagues [12] studied the diagnostic value of serum
PCT levels in 4,698 patients with different types of
CHF. Patients were grouped into CHF (n = 1,364),
CHF with infection (n = 1,183), infection only (n = 1,703)
and healthy controls (n = 448). The PCT levels in patients
with CHF were significantly elevated compared with
healthy controls, while those with infection and CHF had
higher levels than both the infection alone and CHF alone
group (Figure 2). In patients with increasing severity of
CHF, the positive predictive value of PCT decreased
significantly (90.9 in class II CHF with infection to 68.6 in
class IV CHF). If the PCT was negative, however, the
finding was good for ruling out infection in class IV CHF
patients (negative predictive value of 89). Hence, elevated
PCT should not be taken at face value in patients
with CHF and a higher cutoff should be used to define
infection, depending on the severity of heart failure.
In a meta-analysis of seven studies including 1,075
patients, Prkno and colleagues [13] studied the safety
of using a PCT-based regimen in patients with severe
sepsis or septic shock. The 28-day mortality based on
results from four included studies was not different
between the PCT-based regimen and standard treatment
groups, but the PCT group had a shorter duration of
antimicrobial therapy based on five included studies.
The studies included in the meta-analysis had substantial
differences in design and cutoff values for PCT and
included both medical and surgical patients, but the
common theme was that therapy based on PCT leads to
more de-escalation and a shorter duration of antibiotic
therapy, with no adverse impact on mortality. The Stop
Antibiotics on Guidance of Procalcitonin Study (SAPS) is
an ongoing, multicenter, randomized Dutch study of daily
PCT versus standard therapy , currently finishing enroll-
ment, and will be the largest ICU-based trial evaluating the
early stopping of antibiotics based on PCT [14].
Surveillance strategies and antibiotic stewardship
Healthcare bundles in the form of daily goal sheets
and educational sessions have been shown to reduce
the incidence of VAP and related complications, but
Figure 1 Plasma kallistatin levels on day 1 of ICU admission and likelihood of 60-day survival. (A) Receiver operating characteristic curves
determining the cutoff value of day 1 kallistatin (6.5 μg/ml) to discriminate between survivors and nonsurvivors. (B) Kaplan-Meier curves of 60-day
survival with patients grouped according to day 1 kallistatin levels >6.5 μg/ml or <6.5 μg/ml at ICU admission. Log-rank test was performed for
comparisons between the groups. AUC, area under the curve. Adapted from Lin and colleagues [10].
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use. The CDC recently introduced a step-wise approach
for ‘objective’ surveillance of ventilator-associated
events and includes ventilator-associated complications
(VACs), infection-related ventilator-associated complica-
tions (IVACs), as well as possible and probable VAP.
Muscedere and associates [15] studied the clinical
impact and preventability of VACs and IVACs using
prospectively collected data on 1,320 patients fromFigure 2 Differential expression of procalcitonin in different populati
95th percentiles in each category. HF, heart failure; PCT, procalcitonin. Adapanother series and determined the relationship to VAP.
Over four study periods, VACs developed in 10.5% of
patients (n = 139), IVACs in 4.9% (n = 65) and VAP
was noted in 11.2% (n = 148); 39 patients had both a
VAC or IVAC and VAP. Patients who had VACs were
more likely to develop VAP than those who did not
have VACs (28.1% versus 9.2%, P <0.001). Patients
with VACs or IVACs had significantly more ventilator
days, hospital days, and antibiotic days and higher hospitalons. Boxes represent interquartile range, and whiskers the 5th and
ted from Wang and colleagues [12].
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VACs or IVACs. When prevention efforts were under-
taken, they were able to reduce the incidence of VACs and
VAP, but not IVACs, over subsequent periods. In another
study, Hayashi and colleagues [16] compared 153 patients
with VACs to 390 without VACs and noted that patients
who developed VACs had a longer ICU LOS (22 versus
11 days), duration of MV (20 versus 5 days) and use of
antibiotics but no difference in overall ICU mortality and
hospital LOS. VAC definitions identified a ‘potential VAP’
(a VAC with positive culture of respiratory pathogens in
respiratory specimens plus antibiotic prescription with
intention to treat as VAP) in 30.7% of cases, but it was not
specific for VAP and included atelectasis in 16.3% of
patients, acute pulmonary edema in 11.8%, and ARDS in
6.5%. Using electronic records to identify complications
related to ventilation is easy and identifies sick patients,
but many patients with VAP were not identified in both
studies and therefore VACs and IVACs may be different
diseases with different pathobiological causes than VAP.
Sinuff and associates [17] studied the impact of a 2-year
multi-faceted intervention via educational sessions supple-
mented with reminders and led by local opinion leaders on
improving concordance with VAP prevention and treat-
ment guidelines and assessed sustainable behavior changes
in the ICU. Over time, there was more improvement in
prevention strategies than in therapy approaches, and,
overall, a significant increase in guideline concordance
(aggregate concordance (mean (standard deviation)): 50.7%
(6.1), 54.4% (7.1), 56.2% (5.9), 58.7% (6.7); P = 0.007). They
also observed a reduction in VAP rates (events/330
patients: 47 (14.2%), 34 (10.3%), 38 (11.5%), 29 (8.8%);
P = 0.03) over the study period, but ICU mortality and
length of ICU stay were unchanged, despite adjustments for
age and SOFA score. The best concordance rate achieved
was only 58.7% and highlights the potential barriers to
guideline implementation and variable practices that exist
within the community despite multiple reinforcements.
In another study, including 350 patients, investigators
using data from electronic medical records compared the
incidence and outcomes in VAP patients using various
definitions, including the new CDC ventilator-associated
event algorithm, before and after a VAP bundle was
introduced in their institution (pre-bundle period
January 2003 to December 2006 (n = 213); post-bundle
period January 2007 to December 2009 (n = 137)) [18].
Unlike the previous study, VAP and VAC incidence
remained unchanged and was not affected by the imple-
mentation of the VAP bundle despite good compliance.
However, mortality adjusted for severity of illness was less
in the post-bundle period (23% versus 18%, P <0.0001),
although the duration of MV, ICU and hospital LOS
did not change post-bundle introduction. The lack of
reduction in VAP and VAC incidence could have beendue to continuous quality improvement interventions that
were already underway prior to guideline implementation,
but interestingly the newer ventilator-associated event
definitions did not recognize VAP in all patients, similar
to findings from the studies by Muscedere and colleagues
[15] and Hayashi and colleagues [16] discussed above.
Luna and associates [19], in a prospective study of 283
ventilated patients, analyzed if an antibiotic prescription
strategy based on routine endotracheal aspirate (ETA)
culture was better than empiric antibiotic therapy for
VAP, as outlined by the American Thoracic Society
(ATS)/Infectious Disease Society of America (IDSA)
guidelines. Eighty-three patients had VAP and the
ETA and bronchoalveolar lavage (BAL) cultures had
concordance in only 52 culture pairs. Sensitivity for
ETA to predict a BAL-obtained pathogen was 62.4%
(78/125 microorganisms cultured) and was better if
done within 3 days of VAP onset and in recurrent VAP.
Antibiotic decisions made according to the ATS/IDSA
guidelines led to appropriate therapy in 97.9% of patients
compared with 77.4% based on ETA culture, with fewer
antibiotic days using the ETA-based culture. Hence,
using a strategy for VAP diagnosis and treatment decision-
making based on ETA cultures alone could result in
inappropriate therapy but possibly helps with de-escalation
and leads to fewer antibiotic days.
Community-acquired pneumonia and
healthcare-associated pneumonia
Recent studies have confirmed the significant heterogeneity
among HCAP patients and also that the risk for MDR
pathogens has regional differences. In a study including
519 patients with CAP and 419 with HCAP, the authors
compared the performance of Pneumonia Severity Index
(PSI) and CURB-65 risk scores for predicting 30-day
mortality [20]. HCAP patients were sicker, had more
frequent ICU admission, longer length of ICU stay
and higher mortality than CAP patients in this cohort.
The discriminatory power for 30-day mortality, using both
PSI and CURB-65, was lower in HCAP patients than
CAP patients (AUC for PSI = 0.679, CURB-65 = 0.599
in HCAP group versus AUC for PSI = 0.835, CURB
65 = 0.79; P = 0.009). Thus, both scoring systems were
less effective for predicting mortality in HCAP than
in CAP patients, but if used, the PSI scoring system
performed better than CURB-65. In a prospective study
including 1,413 patients (887 CAP and 526 HCAP),
Shindo and associates [21] determined the risk factors
for pathogens resistant to macrolides, beta-lactams and
respiratory fluoroquinolones (CAP-DRPs). HCAP patients
had a higher frequency of CAP-DRPs than CAP patients
(26.6% versus 8.6%) and a higher 30-day mortality
rate (20.3% versus 7.0%). Independent risk factors for
CAP-DRPs were similar in both CAP and HCAP groups,
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previous antibiotic use, gastric acid-suppressive agents,
tube feeding, and non-ambulatory status. The higher the
number of risk factors, the greater the chance of
CAP-DRPs (AUC 0.79, 95% CI 0.74 to 0.84). They
also identified risk factors for methicillin-resistant
Staphylococcus aureus (MRSA), which included dialysis
within 30 days, prior MRSA isolation within the past
90 days, antibiotics in the past 90 days, and gastric
acid-suppressive therapy. However, the presence of a
high frequency of resistant pathogens in this study
group limits generalization and further studies are
needed for external validity of the model.
In another study, Aliberti and colleagues [22] used
probabilistic risk scores for prediction of MDR pathogens
in two independent cohorts admitted to the hospital from
the community (n = 3,474) to validate the previously
reported Shorr and Aliberti risk scores. The prevalence of
MDR pathogens was 7.6% in Barcelona and 3.3% in
Edinburgh and the two scores performed consistently
better than the traditional HCAP classification in both
centers. Maruyama and colleagues [23], in a prospective
study of 425 patients (CAP = 124, HCAP = 321), applied a
therapeutic algorithm based on the presence of MDR risk
factors (immunosuppression, hospitalization within the
last 90 days, poor functional status indicated by a Barthel
Index score <50, and antibiotic therapy within the past
6 months) and severity of illness (need for ICU admission
or requiring MV) to determine its impact on outcomes.
HCAP patients with no or one risk factor were treated
with CAP therapy and those with two or more risk factors
were treated with a hospital acquired pneumonia regimen
based on the ATS/IDSA 2005 guidelines. HCAP patients
with two or more risk factors had a higher incidence of
MDR pathogens and higher mortality than CAP patients
(27.1% versus 2%, P <0.001, and 13.7% versus 5.6%,
P = 0.017, respectively). Although only 53% of HCAP
patients received broad-spectrum antibiotics, using
the algorithm the majority (92.9%) received appropriate
therapy for the identified pathogens. Thus, using this
approach, broad-spectrum antibiotic use can be limited,
even in patients with HCAP. Lacroix and associates [24]
investigated the role of early fiberoptic bronchoscope-
guided distal protected small volume bronchoalveolar lavage
(mini-BAL) in 54 HCAP patients. Mini-BAL helped identify
causative pathogens more efficiently than blood culture
(46.3% versus 11.1%, P <0.01), up to 72% in patients
who did not receive prior antibiotics. Thus, a strategy
based on mini-BAL might help with early identification,
but the authors did not compare length of antibiotic days,
development of resistance or mortality between an
empiric regimen and patients who had mini-BAL.
The practicality of this approach in the non-intubated
HCAP population needs to be validated.Sicot and colleagues [25] evaluated the characteristics
of 161 patients with Panton-Valentine leucocidin (PVL)
community-acquired S. aureus pneumonia from a French
registry, based on methicillin resistance. Both PVL-MRSA
(n = 37, 23%) and PVL-methicillin-sensitive Staphylococcus
aureus (PVL-MSSA; n = 124, 77%) occurred in younger
patients (median age 22.5 years) with no underlying
comorbidities. Airway hemorrhage was more frequent
in PVL-MSSA necrotizing pneumonia compared with
PVL-MRSA (44.2% versus 24.1%, P = 0.056) but there was
no significant difference in mortality (39.4% versus 37.9%),
ICU admission, severity of disease or use of antibiotics
between the two groups. Interestingly, methicillin
resistance was not associated with increased mortality,
but patients with airway hemorrhage had a three-fold
increase in 7- and 30-day mortality (OR 3.75 and
3.68, respectively) and patients treated with an anti-toxin
regimen (clindamycin, linezolid, or rifampicin) had a
better chance of survival (mortality rate 6.1% versus
52.3%, P <0.001) even though the timing of therapy was
not available. This study is one of the largest series on nec-
rotizing community-acquired staphylococcal infection and
shows that, despite the resistance pattern, PVL-associated
S. aureus infection can be a severe disease with high mor-
tality in young patients from the community and that the
use of anti-toxin therapy in suspected patients is associated
with a potential survival advantage.
Viral infection in the critically ill patient
Choi and associates [26] studied the role of viruses in
198 patients with severe pneumonia (64 with CAP and
134 with HCAP) using RT-PCR and BAL fluid (58.1%)
or nasopharyngeal swab (84.1%). Of the patients, 35.9%
(n = 71) had positive bacterial culture, 36.4% (n = 72)
had viral infections, and 9.1% (n = 18) had bacterial-
viral co-infections. Rhinovirus was the most commonly
identified virus (23.6%), followed by parainfluenza virus
(20.8%) and human metapneumovirus (18.1%). Bacterial co-
infection was more common with parainfluenza and influ-
enza viruses and less common with respiratory syncitial
virus and rhinoviruses. There was no difference in mortality
between each group, but of those patients with viral infec-
tion, rhinovirus was associated with the highest mortality
(52.9%), followed by influenza virus (33.3%). This is an in-
teresting study and shows that polymicrobial infection with
viruses and bacteria is not uncommon in patients with
severe pneumonia. However, some study participants
had antibiotics prior to BAL and therefore the negative
bacterial cultures may not have been an accurate finding.
In contrast to the discussion above, bacterial infection
commonly complicates viral respiratory infection and is
often associated with higher morbidity and mortality.
Muscedere and colleagues [27] evaluated the risk of
coexistent or secondarily acquired bacterial respiratory
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with influenza A (H1N1) infection during the 2009
outbreak. They noted that 38% of patients (n = 259)
had at least a positive blood or respiratory culture
during their ICU stay (29.7% had co-existent and
44.4% had ICU-acquired infection; 15.4% had both)
despite almost all patients receiving antibiotics. Patients
with any positive culture had higher morbidity with more
days on the ventilator, longer ICU and hospital LOS and
higher hospital mortality (24.7% versus 19.9%, P = 0.15).
The interesting finding from this study is that influenza
infection (H1N1) is not as mild as previously thought; the
majority of ICU patients required MV and the morbidity
and mortality were high even in patients without bacterial
co-infection. Hung and colleagues [28] in a double-blind,
randomized controlled trial evaluated the use of
hyperimmune IV immunoglobulin (H-IVIG) fractionated
from convalescent plasma of patients who had 2009 H1N1
infection (n = 17) versus normal IV immunoglobulin
(n = 18) in 35 patients with severe H1N1 infection.
Patients who received H-IVIG had significantly lower
viral loads post-treatment and, if treatment was given
within 5 days of onset, had mortality benefit (OR 0.14,
95% CI 0.02 to 0.92, P = 0.04). Although the study is
limited by a relatively small sample size, the H1N1 antibody
present in the convalescent H-IVIG, if used early, offers
potential benefit in the treatment of H1N1 infection.
Nosocomial pneumonia
The ATS/IDSA guidelines recommend antibiotic therapy
based on the risk for MDR pathogens with early onset
infection (within 5 days of admission), generally using
a narrow-spectrum antibiotic regimen. Restrepo and
colleagues [29] examined the microbial cultures of 496
VAP patients from 2 large prospective, randomized,
open-label studies, classifying patients as early- (<5 days
since hospitalization, n = 248) and late-onset VAP (>5 days,
n = 248). Late-onset VAP patients had a higher overall
frequency of Gram-negative pathogens (84.3% versus
75.4%, P = 0.02) and more significant antibiotic exposure
in the prior month (85.5% versus 68.5%, P <0.01).
However, both early- and late-onset VAP patients had
similar rates of MDR pathogens (27.8% and 32.3%,
respectively, P = 0.33). Investigators from the EU-VAP
study divided 485 patients with microbiology-confirmed
nosocomial pneumonia into two groups; group 1 was
early-onset with no MDR risk factors (n = 152) and group
2 was early-onset with MDR risk factors or late-onset
pneumonia [30]. The presence of severe sepsis/septic
shock (OR = 3.7) and pneumonia that developed in a
center with greater than a 25% prevalence of resistant
pathogens (OR = 11.3) was independently associated
with the presence of resistant pathogens in group 1
patients. These findings suggest that most patients withVAP are at risk for MDR pathogens, and that very few can
safely receive narrow-spectrum empiric therapy.
Tumbarello and associates [31] analyzed the impact of
multi-drug resistance on outcomes in 110 patients
admitted to ICU with culture-confirmed PA pneumonia.
Forty-two cases (38%) involved MDR PA, and 9 (8.1%)
were colistin-only susceptible PA. The initial antimicrobial
regimen was inadequate in 56 patients (50.9%) and more
often inadequate among those with MDR PA. Patients
who had initial inappropriate antibiotics had a higher
mortality than those who had appropriate therapy (64.2%
versus 24.7%, P = 0.001) and MDR PA patients treated
with empiric combination therapy had a lower risk of
initial inappropriate antibiotics than those treated with
monotherapy. In a similar study, Pena and colleagues [32]
looked at the impact of MDR in 91 patients with PA VAP,
of which 60 cases were caused by MDR strains, 42 (70%)
of which were extensively drug-resistant. As with the
previous study, VAP patients with susceptible PA received
adequate empiric antibiotic coverage more often, both
empiric and definitive, than patients with MDR pathogens
(68% versus 30%, P <0.001). Although inadequate
antibiotics were an independent risk factor for early
mortality (OR 4.27, P = 0.052) and patients with susceptible
strains had more adequate coverage, those with inadequate
therapy had a higher mortality that could be related
to severity of illness more than to resistance. The
OUTCOMEREA data on PA pneumonias include 393
PA-VAP episodes with multi-drug resistance defined
as resistance to two antibiotics (piperacillin, ceftazidime,
imipenem, colistin, and fluoroquinolones) [33]. MDR
was not related to treatment failure or relapses but
was associated with longer ICU LOS. Fluoroquinolone use
prior to the first episode was associated with increased
risk of treatment failure probably related to the induction
of resistance, but when used in the treatment regimen,
fluoroquinolones decreased the risk of treatment failure.
In another study of 143 confirmed pseudomonal pneumo-
nia patients, serotypes O6 and O11 were more prevalent,
but mortality was higher with O1 (40%) and lower with
O2 (0%); clinical resolution tended to be better with O2
(82%) compared with other serotypes. Higher Acute
Physiology and Chronic Health Evaluation II score was
associated with worse outcomes among all serotypes [34].
Clinically feasible and simple to use predictors of ICU
outcome in patients with ICU-acquired pneumonia are
important in clinical practice. In a prospective observa-
tional study, Esperatti and colleagues [35] determined
the usefulness of a set of predictors of adverse outcomes
(PAOs) in 355 ICU-acquired pneumonia patients and
determined their correlation with serum inflammatory
markers and clinical prognostic scores. The PAOs
were determined 72 to 96 hours after starting antibiotics
(evolutionary criteria), and were considered positive if
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oxygen in arterial blood/fraction of inspired oxygen ratio
since the onset of pneumonia and in the absence of other
causes of worsening oxygenation; 2) requirement for
intubation despite antibiotics for 24 hours; 3) persistence
of fever or hypothermia together with purulent secretions;
4) a 50% or greater increase in pulmonary infiltrates on
chest radiograph; 5) development of septic shock or
multi-organ dysfunction not present on day 1. Fifty
percent of patients had at least one PAO, and had a
higher 28-day mortality (45% versus 19%, P = 0.001), less
mean ventilator-free days (10 versus 12, P = 0.001) and
elevated serum inflammatory markers such as PCT and
C-reactive protein compared with those who did not have
any PAOs. The trend remained significant in patients
who developed VAP, as well as those who had non-
ventilator ICU-acquired pneumonia. The failure to improve
oxygenation (partial pressure of oxygen in arterial blood/
fraction of inspired oxygen) and a worsening SOFA score
over 5 days were independently associated with mortality in
a multivariate analysis.
New insights into treatment strategies
The 2007 ATS/IDSA guidelines recommend using
combination antibiotic therapy in patients with severe
CAP admitted to the ICU. Adrie and colleagues [36]
examined the impact of dual (β-lactam plus macrolide or
fluoroquinolone (n = 394)) versus monotherapy (β-lactam
alone (n = 471)) in immunocompetent severe CAP pa-
tients, using a large prospective database. They found
no significant difference in 60-day mortality between pa-
tients who had dual therapy compared to monotherapy,
and in those who received dual therapy, there was no sur-
vival advantage between the macrolide and fluoroquino-
lone subgroups (subdistribution hazard ratio 1.45, 95% CI
0.78 to 2.70, P = 0.24). Interestingly, patients who had ini-
tial adequate antibiotic therapy had a survival advan-
tage (subdistribution hazard ratio 0.63, 95% CI 0.42
to 0.94.00, P = 0.02) and those who received dual therapy
had a higher frequency of initial adequate antibiotics,
which did not translate into improved survival. Further,
subgroup analysis did not reveal a survival benefit even in
patients with septic shock or Streptococcus pneumoniae
infection receiving dual therapy, but dual therapy did
not increase the development of MDR pathogens or
nosocomial pneumonia. In a similar study including
3,203 hospitalized patients, guideline concordant therapy
(defined as macrolides/β-lactams or respiratory fluoroquino-
lone monotherapy) did not have a mortality benefit com-
pared with discordant therapy, but a composite endpoint of
death or ICU admission was lower in the concordant group
(14.7% versus 29.0%; adjusted OR 0.44, 95% CI 0.36 to 0.54,
P <0.0001) [37]. Most patients received levofloxacin mono-
therapy in the guideline-concordant group (70%) and therewas no significant difference in mortality between patients
who received macrolide/β-lactam antibiotics versus those
who had fluoroquinolone/β-lactams (adjusted OR
0.75, 95% CI 0.395 to 1.42, P = 0.38). The findings from
these studies contradict previous reported studies, but lack
of randomization and possible misclassification bias limits
interpretation.
Antibiotic dosing in critically ill patients is challenging
due to deranged drug metabolism and elimination that
can lead to suboptimal dosing. Extended infusion of
antibiotics with a time-dependent killing mechanism,
such as beta-lactams, has been proposed as a means to
overcome the pharmacokinetic/pharmacodynamic (PK/PD)
alterations in severely ill patients in order to optimize the
time that drug concentration exceeds the minimum
inhibitory concentration (MIC) of the target organism.
Carlier and colleagues [38] studied the effect of augmented
renal clearance on extended infusion of meropenem or
piperacillin/tazobactam (Pip/Tazo) in 61 patients with
sepsis and normal creatinine clearance [38]. Patients
received a loading dose (1 g for meropenem and 4.5 g for
Pip/Tazo) followed by extended infusion usually over
3 hours every 6 hours for Pip/Tazo and 8 hours for mero-
penem. Only 55% of patients achieved a predefined PK/PD
target, and of patients who had augmented renal clearance
(48%), the majority did not achieve the target (76%).
Augmented renal clearance with a clearance >130 ml/
minute was an independent predictor of not achieving
the PK/PD target, but the study was not designed to
look at outcome and treatment failures, and the PK/PD
target may have been set too high. Dulhunty and
colleagues [39], in a double-blind randomized controlled
trial, compared continuous versus intermittent bolus
dosing of Pip/Tazo, meropenem, and ticarcillin-clavulanate
in 60 patients with severe sepsis. Patients in the interven-
tion arm received active infusion and placebo boluses and
controls received placebo infusion and active boluses. The
concentration exceeded the MIC more often in the
intervention group than in controls (81.8% versus 28.6%,
P = 0.001; most with meropenem and least with ticarcillin-
claculanate) and the patients in the intervention group had
a higher clinical cure rate, but there was no difference in
ICU or hospital LOS or mortality. The study reinforces the
dosing options available for critically ill patients based on
PK characteristics, but did not have the statistical power to
determine a mortality benefit, although there was a trend
towards better survival in the intervention arm.
With the growing development of resistance to
beta-lactams, aminoglycosides are advocated for patients
with severe sepsis as part of combination therapy, espe-
cially with PA infection and the bactericidal activity of
aminoglycosides is dependent on peak concentration
(Cpeak) relative to MIC. As noted above, the concentra-
tion of aminoglycoside can change in critically ill patients
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patients with severe sepsis (50% with lung infection)
requiring amikacin, investigators used therapeutic drug
monitoring and dose adjustments to optimize serum con-
centration [40]. Microbiological eradication and clinical
cure were higher in patients who achieved initial optimal
Cpeak/MIC and were proportionately higher with higher
target concentration. Patients who achieved the target
concentration after 3 days had a worse clinical cure and
microbiological eradication than those who achieved this
goal on the first day. Renal failure was seen in 24% of
patients and was more likely in those with impaired
clearance and higher minimum concentration.
Inhalation antibiotics have the potential advantage of
achieving high alveolar concentrations with minimal
systemic side effects. In a matched 1:1 case control study,
Tumbarello and colleagues [41] studied aerosolized colistin
(given via jet nebulizer or ultrasonic nebulizer) as an
adjunctive treatment to intravenous therapy with the
same drug in 208 VAP patients with positive cultures
for Gram-negative MDR pathogens susceptible only to
colistin. Patients receiving aerosolized therapy in conjunc-
tion with intravenous colistin had a higher clinical cure
rate compared with controls (69.2% versus 54.8%, P = 0.03)
and fewer days on the ventilator after onset of VAP
(8 versus 12 days, P = 0.001), but no difference in
overall mortality or ICU LOS. Also, there was no difference
in the rate of new-onset kidney failure between the two
groups. The study results are in contrast to previous
reports with aerosolized colistin providing only modest
benefits. In this study the medication was delivered in the
majority of patients using conventional ventilators with jet
nebulizers and the local concentration of antibiotics
could not be determined. In view of the reported increased
incidence of drug-resistant pathogens causing VAP and the
potential treatment alternative with aerosolized colistin,
further randomized controlled studies are needed prior to
generalization of the results.
In a study looking at factors influencing antibiotic
de-escalation in 229 patients admitted to ICU with
sepsis, only 51.1% of patients had the number of anti-
biotics reduced or switched to a narrower spectrum
[42]. However, there was no difference in mortality rate,
ICU LOS or duration of MV between patients who had
de-escalation compared with those with no de-escalation.
In those patients who did not have de-escalation, 15%
had no de-escalation despite meeting criteria. Narrow-
spectrum initial antibiotic therapy (OR 0.1, 95% CI
0.0 to 0.1, P <0.001) and infection with an MDR bacteria
(OR 0.2, 95% CI 0.1 to 0.7, P = 0.006) were factors prevent-
ing de-escalation.
Duration of antibiotic treatment for nosocomial pneu-
monia is not clearly defined, and previous studies have
shown that a short duration may be as clinically effectiveas a longer duration (>14 days) and more cost-effective.
A meta-analysis of four randomized controlled trials
(including 883 patients) comparing short (7 to 8 days)
with long (10 to 15 days) duration regimens in patients
with VAP showed no difference in mortality, ICU LOS
or MV between the two groups, and more antibiotic-
free days in the short course group [43]. There was a
trend towards more relapses due to non-fermenting
Gram-negative bacilli in the shorter duration antibiotic
cohort. In another observational study, including 89
suspected VAP patients with negative BAL results, investi-
gators compared the effects of early discontinuation
(antibiotics stopped within 1 day of final negative
quantitative BAL culture results) with late discontinuation
of antibiotics (more than 1 day after negative final BAL
cultures) [44]. There was no difference in mortality
between early discontinuation (25.0%) and late discontinu-
ation (30.6%) patients (P = 0.642). Clinical resolution as
noted by Clinical Pulmonary Infection Score was similar
in both groups and patients with late discontinuation
had a longer duration of antibiotic therapy (9 versus
4 days, P <0.001). Interestingly, patients with early
discontinuation developed less frequent superinfections
compared with late discontinuation patients (22.5% versus
42.9%, P = 0.008). These results add credence to the value
of de-escalation for VAP patients and to the possibility
that longer antibiotic courses may cause microbial persist-
ence and selection pressure leading to the development of
microbial resistance.
Prevention
Prophylactic systemic antibiotics have a role in preventing
early-onset VAP in closed head injury patients. Valles and
colleagues [45] evaluated the role of single-dose antibiotics
within 4 hours of intubation (ceftriaxone 2 g intraven-
ously; 1 g ertapenem in those with hypersensitivity to
beta-lactam; 500 mg levofloxacin in those with anaphyl-
axis to beta-lactam) in the prevention of early-onset VAP
or ventilator-associated tracheobronchitis in comatose
patients. They compared 71 patients who received prophy-
laxis to 58 historical cohorts. The patients who received
prophylaxis had fewer microbiologically confirmed cases of
VAP (7% versus 27.6%, OR 0.11, P = 0.009), less MV days,
and shorter ICU LOS. However, there was no differ-
ence in mortality or hospital LOS between the two
groups. Although there was no increased incidence of
MDR pathogens in the prophylaxis group with late-
onset VAP, the study patients did not have surveil-
lance cultures and hence the rate of colonization is
unknown. Prophylactic antibiotic at the time of intub-
ation in high-risk patients at risk for VAP is an inter-
esting concept and further prospective randomized
controlled studies are required prior to generalization
of the results.
Note: This article is part of a collection of Year in review
articles in Critical Care. Other articles in this series can be
found at [49].
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modulatory effects and their use in patients with pneumo-
nia had previously been reported to lead to beneficial
outcomes. Papazian and associates in a double-blind,
parallel-group study, randomized VAP patients (defined as
having a Clinical Pulmonary Infection Score >5) to receive
simvastatin (60 mg) or placebo [46]. The authors
planned to enroll 1,002 patients, but the study was
stopped prematurely because of futility after enrolling
153 in the intervention arm and 147 in the control
group. There was no significant difference in 28-day
mortality (6% absolute increase with simvastatin) or
other secondary outcomes, including duration of MV,
coronary events, ARDS, or adverse side effects between
the two groups. However, of those patients naive to prior
statin use, the 28-day mortality was higher in the pla-
cebo arm (28% versus 5%, P = 0.01). Although this trial
was underpowered to highlight any marginal beneficial
effects of statins, the results are similar to another re-
cent trial exploring the role of statins in sepsis that also
did not find any difference in levels of interleukin-6,
but possible beneficial effects in continuing chronic
statin therapy [47].
Probiotics may restore non-pathogenic gut flora and
the value of their use in critically ill patients has been
inconclusive. Barraud and associates [48] conducted a
meta-analysis including 13 randomized studies with
1,439 patients to evaluate the use of probiotics (most
with Lactobacillus sp.) in the ICU. Probiotic use did
not have a significant impact on mortality or the duration
of MV. However, probiotic use resulted in a significant
decrease in nosocomial pneumonia even after adjustment
for heterogeneity (OR 0.54, 95% CI 0.36 to 0.79) and
also led to a shorter ICU LOS. Use of probiotics could
potentially prevent gastric colonization by pathogenic
bacteria and might explain the beneficial effects seen with
ICU-acquired pneumonia. Whether this should be added
to VAP prevention measures is still to be determined
and will need further large trials, with VAP as the primary
end point.
Conclusion
Respiratory infections remain the most common cause
of sepsis and septic shock, with Gram-negatives being
slightly more common than Gram-positives. Some patients
have sepsis with negative cultures and these patients may
have a better prognosis than those with positive cultures.
Severe infection is part of a multiple system illness,
and some recent data have examined the relationship
of pneumonia to cognitive impairment, showing that
infection can lead to cognitive decline, possibly related to
inflammatory cytokines, while at the same time patients
who develop pneumonia may be more cognitively
impaired than those without pneumonia. Many episodesof pneumonia result from gastric aspiration, but recent
investigations have shown that development of VAP
could not be prevented even with enteral feeding and
close attention to gastric residual volume. One alternative
is to place feeding tubes directly into the small bowel,
which may reduce pneumonia risk but not have an impact
on mortality.
Biomarkers may help us guide the need for therapy, the
duration of therapy for pneumonia, and the prognosis for
survival, but most data have been collected with serum
PCT measurements. Recent studies suggest that kallistatin
is a protective hormokine, and that, in the setting of septic
shock, low levels may predict adverse outcomes such as
ARDS and death. Another biomarker, presepsin, is elevated
in severe sepsis patients who die. PCT has been used to
separate patients with infection from those without infec-
tion, but in the presence of CHF new data suggest that low
levels may rule out infection, but that severe heart failure
itself can falsely elevate levels.
The diagnosis of VAP remains confusing, and new data
have shown the limited value of the CDC definition of
VACs. VACs include a number of non-infectious diagnoses,
and many patients with VAP do not have aVAC. Some data
suggest that VACs can be prevented, but there are also
studies showing that the currently available ventilator bun-
dles cannot prevent them. In the management of CAP and
VAP, it is important to account for MDR pathogens in
empiric therapy. Outside the hospital, there are patients
who develop HCAP and many of these are also at risk for
MDR pathogens. New studies have suggested strategies to
identify patients at risk for resistant pathogen infection, and
therapies that optimize efficacy, without the overuse of
broad-spectrum therapy. The optimal therapy of MDR
pathogens is being explored, but for MRSA CAP, the use of
anti-toxin therapy may improve outcome. In VAP, the role
of resistance in determining outcome is uncertain, but most
studies suggest an interaction between drug susceptibility
and disease severity. Optimizing the therapy of MDR path-
ogens is being explored in a number of ways, including the
use of modified dosing regimens, and inhaled antibiotics
for pneumonia. Our enhanced understanding of altered
renal clearance in severe infection has led to renewed
efforts to provide enough antibiotic to seriously ill patients,
and to avoid the use of too low a dose of an effective agent.
In the future, we will continue our efforts at pneumonia
prevention, but this will require a continued understanding
of disease pathogenesis, the use of prevention bundles
and the application of standard therapies in novel ways
(as demonstrated with studies of statins).
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